In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer
- PMID: 7857701
- DOI: 10.1016/0959-8049(94)00343-4
In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer
Abstract
We have previously shown that 3 weeks of treatment with tamoxifen, of patients with primary breast carcinomas, increased cytosolic cathepsin D protein in oestrogen receptor (ER) positive tumours [Maudelonde et al., Cancer 1989, 63, 1265-1270]. In order to investigate the mechanism of this increase and to eliminate a transient flare-up effect, we semi-quantified cathepsin D RNA levels by in situ hybridisation in 32 breast carcinomas from patients treated with tamoxifen for 3 weeks prior to surgery and in 35 breast cancer patients receiving no tamoxifen. We found that tamoxifen increased cathepsin D RNA level regardless of the ER status of the tumours. In ER positive tumours, tamoxifen increased the cathepsin D RNA level to the same extent as cytosolic cathepsin D protein but not in ER negative tumours. The induction of cathepsin D RNA by tamoxifen in ER positive tumours was probably due to its agonist activity, also observed in vitro in breast cancer cell lines. These results suggest that the cathepsin D gene is inducible by oestrogens in ER positive breast cancer as it is in breast cancer cell lines.
Similar articles
-
Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group.Eur J Cancer. 1994;30A(14):2042-8. doi: 10.1016/0959-8049(94)00307-q. Eur J Cancer. 1994. PMID: 7857700
-
Tamoxifen treatment increases the concentration of 52K-cathepsin D and its precursor in breast cancer tissue.Cancer. 1989 Apr 1;63(7):1265-70. doi: 10.1002/1097-0142(19890401)63:7<1265::aid-cncr2820630706>3.0.co;2-z. Cancer. 1989. PMID: 2920355
-
Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.Br J Cancer. 1989 May;59(5):727-38. doi: 10.1038/bjc.1989.153. Br J Cancer. 1989. PMID: 2736207 Free PMC article.
-
Cathepsin D in breast cancer.Breast Cancer Res Treat. 1990 Jul;16(1):3-13. doi: 10.1007/BF01806570. Breast Cancer Res Treat. 1990. PMID: 2207345 Review.
-
[Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].C R Seances Soc Biol Fil. 1998;192(2):241-51. C R Seances Soc Biol Fil. 1998. PMID: 9841098 Review. French.
Cited by
-
Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.Breast Cancer Res Treat. 2024 Jul;206(1):143-153. doi: 10.1007/s10549-024-07293-y. Epub 2024 Apr 5. Breast Cancer Res Treat. 2024. PMID: 38578521 Free PMC article.
-
Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.Br J Cancer. 1999 Feb;79(5-6):909-14. doi: 10.1038/sj.bjc.6690145. Br J Cancer. 1999. PMID: 10070889 Free PMC article.
-
Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.Breast Cancer Res Treat. 1996;38(2):217-26. doi: 10.1007/BF01806676. Breast Cancer Res Treat. 1996. PMID: 8861840
-
Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.Br J Cancer. 1998 Dec;78(12):1645-52. doi: 10.1038/bjc.1998.737. Br J Cancer. 1998. PMID: 9862578 Free PMC article. Clinical Trial.
-
Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780.Clin Exp Metastasis. 1997 Jul;15(4):349-60. doi: 10.1023/a:1018489819092. Clin Exp Metastasis. 1997. PMID: 9219723
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical